Abstract:Non- alcoholic fatty liver disease is a high-risk factor for the morbidity and mortality of type 2 diabetes mellitus. Thus, we conducted a meta-analysis to investigate whether the microRNAs associated with non-alcoholic fatty liver disease are associated with diabetes and their potential to predict diabetes in non-alcoholic fatty liver disease individuals. We conducted a systematic literature search using PubMed, Cochrane library and Embase databases. The literature about circulating microRNA levels in nonalcoholic fatty liver disease individuals was screened according to the inclusion and exclusion criteria. The sensitivity, specificity and area under curve of different microRNAs were summarized. These microRNAs with higher diagnostic efficacy and stability were selected for further analysis in people with diabetes. In all, 10 of 1950 studies determining microRNA expression profiles in non-alcoholic fatty liver disease were included in the final analysis. Using area under curve >= 0.7 as the criterion, we screened out 10 microRNAs that have moderate diagnostic efficacy in non-alcoholic fatty liver disease, including microRNA-122, microRNN-34a, microRNA-99a, microRNA-16, microRNA- 379, microRNA-197, microRNA-181d, microRNA- 146b, microRNA-375 and microRNA-12. The pooled area under curve of microRNA-122 and microRNA-34a in the diagnosis of non-alcoholic fatty liver disease was 0.88 (95 % confidence interval: 0.81-0.96) and 0.86 (95 % confidence interval: 0.82-0.91), respectively. Further, 30 of 2674 studies related to diabetes and the above microRNA were included in the final analysis. The results showed that microRNA-122 and microRNA-34a showed higher stability in non-alcoholic fatty liver disease and diabetes. In conclusion, microRNA-122 and microRNA-34a are common biomarkers of both non-alcoholic fatty liver disease and type 2 diabetes mellitus. However, whether they can be used as effective biomarkers for the early prediction of diabetes in patients with non-alcoholic fatty liver disease lacks valid evidence.

miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

Potential roles of miR-152 in nonalcoholic fatty liver disease by the bioinformatic analysis

Circulating miRNAs as Novel Diagnostic Biomarkers in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

MicroRNAs As Biomarkers and Regulators of Nonalcoholic Fatty Liver Disease

MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease

miRNAs in non-alcoholic fatty liver disease

MicroRNAs and Nonalcoholic Steatohepatitis: A Review

MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease.

Differential Expression of Micrornas in Mouse Liver under Aberrant Energy Metabolic Status

MicroRNAs in metabolic dysfunction-associated diseases: Pathogenesis and therapeutic opportunities

‘Micro‐managers’ of Hepatic Lipid Metabolism and NAFLD

LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis

Association Between Diagnostic Micrornas of Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Meta-Analysis

Elucidation of novel miRNA candidates and their role in unraveling the pathology of Non-Alcoholic Fatty Liver Disease

Roles of Micrornas in Immunopathogenesis of Non-Alcoholic Fatty Liver Disease Revealed by Integrated Analysis of Microrna and Mrna Expression Profiles

The Critical Role of microRNA-21 in Non-alcoholic Fatty Liver Disease Pathogenesis

Inflammation-related miRNAs in obesity, CVD, and NAFLD

Liver-derived Exosomal miRNA in NAFLD: Mechanisms of Action, Biomarkers, and Therapeutic Applications

Plasma Mir-17, Mir-20A, Mir-20B and Mir-122 As Potential Biomarkers for Diagnosis of NAFLD in Type 2 Diabetes Mellitus Patients.